| Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'16 | Sep'16 | Jun'16 |
|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | |||||||||
Net loss | |||||||||
-74,061 | -72,298 | -74,891 | -72,282 | 0 | 0 | 0 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||
Research and development-licenses acquired, expensed | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Non-cash research and development expenses | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Depreciation | |||||||||
82 | 61 | 48 | 32 | 0 | 0 | 0 | - | - | - |
Amortization of debt discount and debt issuance costs | |||||||||
955 | 896 | 879 | 646 | 0 | 0 | 0 | - | - | - |
Stock-based compensation | |||||||||
11,080 | 11,426 | 12,887 | 12,490 | 0 | 0 | 0 | - | - | - |
Other non-cash items | |||||||||
- | 0 | 0 | - | - | 0 | 0 | - | - | - |
Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | |||||||||
-1,718 | -1,754 | 225 | 612 | 0 | 0 | 0 | - | - | - |
Inventory | |||||||||
2,902 | 3,604 | 4,310 | 4,390 | 0 | 0 | 0 | - | - | - |
Prepaid expenses | |||||||||
-361 | -1,017 | 98 | 768 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | |||||||||
1,791 | 1,004 | 37 | -482 | 0 | 0 | 0 | 0 | 0 | 0 |
Accrued expenses | |||||||||
-1,981 | 1,749 | 9,330 | 10,280 | 0 | 0 | 0 | 0 | 0 | 0 |
Accrued interest | |||||||||
107 | 53 | 73 | -926 | 0 | 0 | 0 | - | - | - |
Due to related party | |||||||||
0 | 17 | 13 | -62 | 0 | 0 | 0 | 0 | 0 | 0 |
Other liabilities | |||||||||
- | - | 0 | - | - | - | 0 | - | - | - |
Net cash used in operating activities | |||||||||
-64,720 | -57,885 | -53,869 | -53,666 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flows from investing activities | |||||||||
Purchases of furniture and equipment | |||||||||
384 | 147 | 257 | 367 | 0 | 0 | 0 | - | - | - |
Net cash used in investing activities | |||||||||
-384 | -147 | -257 | -367 | 0 | 0 | 0 | - | - | - |
Cash flows from financing activities | |||||||||
Payment of note payable | |||||||||
0 | 0 | 0 | 31,077 | 0 | 0 | 0 | - | - | - |
Payment of term loan, including a $0.6 million prepayment fee | |||||||||
0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - |
Capital contribution - PBM Capital | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Proceeds from exercise of stock options | |||||||||
2,021 | 465 | 194 | 139 | 0 | 0 | 0 | - | - | - |
Proceeds from the issuance of common stock | |||||||||
0 | 0 | 0 | 80,000 | 0 | 0 | 0 | - | - | - |
Payment of offering cost in connection with issuance of common stock | |||||||||
0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - |
Net cash provided by financing activities | |||||||||
11,525 | 119 | 19,932 | 63,753 | 0 | 0 | 0 | 0 | 0 | 0 |
Net change in cash and equivalents | |||||||||
0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - |
Net increase in cash and equivalents | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |
Supplemental disclosure of cash flow information: | |||||||||
Cash paid for interest | |||||||||
1,485 | 1,286 | 1,172 | 2,156 | 0 | 0 | 0 | - | - | - |
Supplemental disclosure of noncash investing and financing activities: | |||||||||
Accrued offering costs | |||||||||
- | - | 0 | - | - | - | 0 | - | - | - |
Shares issued from the early exercise of options | |||||||||
0 | 0 | 0 | 100 | 0 | 0 | 0 | - | - | - |
Subscription receivable | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Capital contribution - PBM Capital Investments, LLC - payment of AkaRx upfront purchase price | |||||||||
- | - | - | - | - | - | - | 0 | 0 | 0 |